湖南南新制药股份有限公司股票交易异常波动公告

Core Viewpoint - Hunan Nanxin Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative increase of 30% over three consecutive trading days, prompting the company to disclose information regarding its ongoing asset acquisition plans and the normalcy of its operations [2][3]. Group 1: Stock Trading Anomaly - The company's stock price increased by a cumulative 30% over three trading days (July 28, 29, and 30, 2025), which is classified as an abnormal trading situation according to the Shanghai Stock Exchange regulations [2][3]. - The company is currently planning to acquire a domestic pharmaceutical technology asset group, but it is uncertain whether this will constitute a major asset restructuring [2][5]. Group 2: Company Operations and Major Events - The company conducted a self-inspection and confirmed that its daily operations are normal, with no significant changes in the market environment or industry policies [4]. - As of the announcement date, there are no undisclosed major events related to the company, aside from the ongoing acquisition plans [5]. Group 3: Media and Market Rumors - The company has not identified any recent media reports that could have significantly impacted its stock price [6]. Group 4: Board Statement and Commitments - The board of directors confirmed that there are no undisclosed matters that should be reported according to the relevant regulations, and they have not been made aware of any information that could significantly affect the company's stock price [7].